First European Medicines Agency (EMA) and European Association for the Study of Diabetes (EASD) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 September 2025, 10:30 (CEST) to 26 September 2025, 12:00 (CEST)

Submitted by Anonymous (not verified) on 11 November 2025 - 9:38

First European Medicines Agency (EMA) and European Association for the Study of Diabetes (EASD) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 September 2025, 10:30 (CEST) to 26 September 2025, 12:00 (CEST)

Opinion/decision on a Paediatric investigation plan (PIP): Velsipity, etrasimod, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0321/2024

Submitted by Anonymous (not verified) on 10 November 2025 - 16:54

Opinion/decision on a Paediatric investigation plan (PIP): Velsipity, etrasimod, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0321/2024

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 38, Status: Authorised

Submitted by Anonymous (not verified) on 10 November 2025 - 16:45

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Dectova, zanamivir, Date of authorisation: 26/04/2019, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 10 November 2025 - 14:25

Human medicines European public assessment report (EPAR): Dectova, zanamivir, Date of authorisation: 26/04/2019, Revision: 8, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness